Member access

4-Traders Homepage  >  Shares  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)

27
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra
12/12/2014 12/15/2014 12/16/2014 12/17/2014 12/18/2014 Date
85.42(c) 84.74(c) 83.44(c) 84.59(c) 86.72(c) Last
79 361 82 930 209 086 84 109 106 858 Volume
-1.31% -0.80% -1.53% +1.38% +2.52% Change
More quotes
Company
MorphoSys AG is engaged in the development of antibodies for therapeutic, diagnostic, and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development, and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 63,8 M
EBIT 2014 -9,91 M
Net income 2014 -8,87 M
Finance 2014 171 M
Yield 2014 -
Sales 2015 68,0 M
EBIT 2015 -13,2 M
Net income 2015 -11,4 M
Finance 2015 159 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 33,2x
EV / Sales 2015 31,4x
Capitalization 2 293 M
More Financials
Latest news on MORPHOSYS AG
4h ago MORPHOSYS : MOR208 Program Receives Positive Opinion for Orphan Medicinal Produc..
4h ago MORPHOSYS : Partner Roche Provides Update on Trial of Gantenerumab in Prodromal ..
4h ago MORPHOSYS : Partner Roche Provides Update on Trial of Gantenerumab in Prodromal ..
4d ago MORPHOSYS : MOR208 Program Receives Positive Opinion for Orphan Medicinal Produc..
12/10 MORPHOSYS : and Xencor Release Final Results from Phase 1/2a Trial of Mor208
12/08 MORPHOSYS : Presents Updated Phase 2 Clinical Results for MOR208 Monotherapy in ..
12/08 MORPHOSYS : Presents Updated Phase 2 Clinical Results for MOR208 Monotherapy in ..
12/06 MORPHOSYS : and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (Xm..
More news
Sector news
1d ago ALNYLAM PHARMACEUTICALS : Elects Michael W. Bonney to Its Board of Directors
2d ago MEDIVATION : Announces Participation at Upcoming Investor Conference
2d ago QUINTILES TRANSNATIONAL : CEO Tom Pike to Present at J.P. Morgan Healthcare Conf..
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF